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Varicella-zoster virus (VZV) is the only human herpes virus for which a vaccine has been licensed. A clinical VZV isolate,
designated the parent Oka (pOka) strain was passed in human and non-human fibroblasts to produce vaccine Oka (vOka). The pOka and
vOka viruses exhibit similar infectivity in cultured cells but healthy susceptible individuals given vaccines derived from vOka rarely
develop the cutaneous vesicular lesions characteristic of varicella. Inoculation of skin xenografts in the SCIDhu mouse model of VZV
pathogenesis demonstrated that vOka had a reduced capacity to replicate in differentiated human epidermal cells in vivo (Moffat, J.F.,
Zerboni, L., Kinchington, P.R., Grose, C., Kaneshima, H., Arvin A.M., 1998a. Attenuation of the vaccine Oka strain of varicella-zoster
virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol. 72:965–74). In order to
investigate the attenuation of vOka in skin, we made chimeric pOka and vOka recombinant viruses from VZV cosmids. Six chimeric
pOka/vOka viruses were generated using cosmid sets that incorporate linear overlapping fragments of VZV DNA from cells infected
with pOka or vOka. The cosmid sets consist of pOka and vOka DNA segments that have identical restriction sites. As expected, the
growth kinetics and plaque morphologies of the six chimeric pOka/vOka viruses were indistinguishable in vitro. However, the chimeric
viruses exhibited varying capacities to replicate when evaluated in skin xenografts in vivo. The presence of ORFs 30–55 from the pOka
genome was sufficient to maintain wild-type infectivity in skin. Chimeric viruses containing different vOka components retained the
attenuation phenotype, suggesting that vOka attenuation is multi-factorial and can be produced by genes from different regions of the
vOka genome.
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Varicella-zoster virus (VZV) belongs to the genus
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E-mail address: zerboni@stanford.edu (L. Zerboni).family Herpesviridae. VZV has a large double-stranded
DNA genome of approximately 125 kb that encodes at least
71 genes. Like other herpesviruses, the VZV genome has
two unique regions, referred to as unique long (UL) and
unique short (US), which are flanked by repeated sequences
(Davison and Scott, 1986). Three VZVopen reading frames
(ORFs) are located within the inverted repeat regions; the
ORFs 62, 63, and 64 from the internal repeat region are05) 337–346
L. Zerboni et al. / Virology 332 (2005) 337–346338duplicated at the end of the VZV genome as ORFs 71, 70,
and 69. The immediate early 62 protein (IE62) encoded by
the duplicate ORF62/71 is the major VZV transactivator;
IE62 protein is required for transcription of all viral genes
that have been evaluated (Kinchington et al., 1992).
VZV has a very limited host range, producing disease in
humans only (Arvin, 2001a, 2001b). Initial replication is
thought to occur in epithelial cells of the upper respiratory
tract where VZV may gain access to tonsil T cells (Ku et al.,
2002). Infected Tcells appear to transport the virus to the skin
where it causes the characteristic vesicular rash of varicella
(chicken pox) (Koropchak et al., 1989; Ku et al., 2004; Ozaki
et al., 1986; Soong et al., 2000). VZVexhibits the neurotropic
characteristics of the other alphaherpesviruses, and estab-
lishes latency in sensory nerve ganglia (Kennedy et al., 1998;
Cohen and Straus, 2001). The reactivation of latent VZV
causes zoster. Zoster is usually associated with a vesicular
rash and acute pain in one cutaneous dermatome, indicating
that VZV migrates along axons from a single ganglion. Even
though varicella is usually uncomplicated, prior to vaccine
licensure, annual varicella epidemics resulted in hospital-
ization of 5 per 1000 children and an average of 100 deaths
each year in the United States. Zoster is often associated with
the morbidity of postherpetic neuralgia (PHN) and immuno-
compromised individuals may develop life-threatening dis-
semination of the virus to lung, liver, brain, and other organs
during VZV reactivation.
After 15 years of clinical trials, a live attenuated VZV
vaccine (Oka-Merck; VARIVAX) was licensed in the United
States in 1995. The varicella vaccine was generated by serial
passage of a wild-type VZV isolate, referred to as the parent
Oka (pOka) virus, in human and guinea pig embryo
fibroblasts. This procedure resulted in attenuation when
susceptible children were inoculated with vOka (Takahashi et
al., 1974; Johnson et al., 1997). In contrast, early reports
showed that injection of VZV directly from varicella skin
lesions caused typical varicella (von Bokay, 1909). Subcuta-
neous inoculation of the Oka-Merck preparation of varicella
vaccine induced seroconversion in 95% of healthy children
and varicella vaccine efficacy has been approximately 85% in
pre- and post-licensure evaluations of protection against
wild-type VZV. Vaccination was associated with a mild
vesicular rash in fewer than 5% of vaccine recipients (White,
1996). The incidence of zoster may also be reduced among
vaccine recipients (Broyer et al., 1997; Kamiya et al., 1984;
Plotkin et al., 1989; Sauerbrei et al., 1997; White, 1996).
The clinical experience with all varicella vaccines,
including the Merck, Biken, and SKB preparations, has
established that vOka in the vaccine preparations is attenu-
ated. However, the mechanisms that account for this clinical
phenotype of reduced virulence are not understood. In
general, while the sequence of the VZV genome (Dumas
strain) was determined in 1986, investigating the molecular
biology of VZV has been complicated by the extremely cell-
associated nature of its replication in vitro (Arvin, 2001a,
2001b; Davison and Scott, 1986). This characteristichindered the construction of VZV recombinants with
mutations in the viral genome by standard methods of
homologous recombination. This problem has been solved
by using cosmid-based methods for VZV mutagenesis that
allow efficient generation of viral mutants (Cohen and Seidel,
1993; Kemble et al., 2000; Mallory et al., 1997; Niizuma et
al., 2003). In parallel, the development of the SCIDhu model
for studies of VZV pathogenesis has made it possible to
overcome the barriers posed by the restricted host range of
VZVand to assess VZV virulence in human skin and T cells
located within intact tissue microenvironments in vivo
(Moffat et al., 1995). Using this SCIDhu model, we found
that the varicella vaccine (Oka-Merck) was attenuated for
replication in skin when compared to pOka, but retained
infectivity for differentiated human T cells (Moffat et al.,
1998a, 1998b). Since SCID mice lack the capacity to mount
an adaptive immune response, these experiments indicated
that the clinical attenuation of the varicella vaccine was
intrinsic, reflecting genetic changes that altered virulence in
skin, rather than being due to other factors, such as the
infectious virus dose or route of inoculation.
The purpose of these experiments was to explore the
attenuation of varicella vaccines derived from vOka. Recent
sequencing information indicates that Biken and Oka-Merck
vaccine preparations contain a mixture of VZV genomes
that have heterogenous changes when compared to pOka
(Gomi et al., 2002; Quinlivan et al., 2004). We used our
VZV cosmids, which consists of overlapping fragments of
VZV DNA from cells infected with pOka or vOka, to
further investigate the altered virulence of vOka. Six
chimeric pOka/vOka viruses were generated and evaluated
for their relative infectivity in human skin xenografts in the
SCIDhu model in vivo.Results
Generation and sequencing of pOka/vOka chimeric viruses
The method for generating vOka recombinant viruses
from four overlapping fragments of genomic DNA in
SuperCos1 cosmid vectors (Stratagene) has been described
(Kemble et al., 2000; Mallory et al., 1997); subsequently,
we made a set of four pOka cosmids with the same
restriction sites as used for vOka cosmids, as well as five
cosmid systems from vOka and pOka (Besser et al., 2003;
Niizuma et al., 2003; Sato et al., 2003). Chimeric viruses
were generated by co-transfection of combinations of the
pOka and vOka cosmid sets (Fig. 1). Six pOka/vOka
recombinants were generated from these cosmids (Fig. 2A).
The heterogenous junctions, designated junctions 1, 2, and
3, of the chimeric viruses were sequenced along with
approximately 600 bp on each side of the overlapping
regions and the results were compared to the Oka-Merck
vaccine sequence. These comparisons showed complete
matches, with only a few exceptions (Fig. 2B). Differences
Fig. 1. Cosmids used to generate pOka/vOka recombinant viruses. Panel A depicts the four cosmid sets for vOka and pOka, with the designations used for the
vOka cosmid indicated first, for example, Fsp4, followed by the pOka cosmid designation after the d/T mark, for example, Fsp73. Panel B shows the five cosmid
sets generated from vOka and pOka DNA.
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nucleotide in the vOka sequence. Of the chimeric viruses
that had an overlap at junction 1, the G and H chimeras
had an A (pOka) instead of G, found in vOka, at position
26075. The A to G change from vOka in these chimeras
was in ORF18, which encodes VZV ribonucleotide
reductase-2; the substitution did not alter the amino acid.
As the vOka vaccine constitutes mixtures of VZV
genomes, our sequence comparison identified some local-
ized sequence heterogeneity in the Oka-Merck vaccine
sequence. Among the chimeras with an overlap at junction
2, the D, G, K, and M chimeras had G instead of G/A in
vOka at position 58474. Chimera D had G, chimeras K and
M had A, and chimera G had G/A polymorphism at
position 58793. All chimeras had A instead of G/A in
vOka at position 59166. These changes were in ORF31,
which encodes glycoprotein B; the changes at 58474 and
58793 affected the amino acid sequence of gB by
substituting valine for isoleucine (I58474V) and glutamine
for arginine (Q58793R), respectively; the change at 59166
did not alter the amino acid. The vOka sequence had six
A’s at positions 60147–152 in the presumed non-coding
region between ORF32 and ORF33, while chimera M had
11 A’s, and the other chimeras had 10 A’s. Of the chimeras
that had an overlap at junction 3, D, G, H, and M had T
instead of the C found in vOka at position 94032, which
was within ORF54. The change did not alter the leucine
residue. Sequencing of ORF62, and its repeat, ORF71, in
the pOka and vOka cosmids identified two nucleotide
changes in vOka compared to pOka that resulted in altered
amino acids, including A to G at position 2872 (A2872),
changing arginine to glycine at amino acid 958, and T to Cat position 3172 (T3172C) changing tyrosine to histidine at
amino acid 1058 (Y1058H) (Sato et al., 2003).
Growth characteristics of pOka/vOka chimeric viruses
in vitro
Analysis by infectious center assay demonstrated that the
six pOka/vOka chimeric viruses had growth kinetics that
were indistinguishable in melanoma cells (Fig. 3). These
observations were expected because replication, as well as
plaque morphologies, of pOka and vOka do not differ in
vitro. All six chimeras were transferred to HELF cells for
inoculation of SCIDhu skin xenografts. No differences in
growth or plaque morphology were observed in fibroblasts.
Growth characteristics in SCIDhu skin implants
Whereas replication is not altered in cultured cells,
attenuation of vOka can be demonstrated in SCIDhu skin
xenografts in vivo (Moffat et al., 1998a, 1998b). The
comparison of the pOka and vOka viruses generated from
pOka and vOka cosmids, respectively, showed that the
recombinant viruses retained these differences (Fig. 4).
When infectious virus yields were assessed by infectious
center assay over a 28-day time course, the mean titer for
pOka replication in skin at day 28 was 2.8 104 pfu/implant
compared to 0.9  104 pfu/implant for vOka (P b 0.05).
The six chimeric pOka/vOka viruses were evaluated for
replication in skin and compared to pOka and vOka (Fig. 4).
By this analysis, chimeras D and G had mean day 28 titers of
3.0  104 and 2.9  104 pfu/implant, which were
comparable to pOka. Chimera K had a more intermediate
Fig. 3. Replication of pOka/vOka chimeric viruses in vitro. Yields of
infectious virus were determined for 6 days after inoculation of melanoma
cells with 103 pfu of the recombinant viruses; titers are given as the mean
for quadruplicate wells at each time point. The X axis shows the days after
inoculation when infected cell monolayers were harvested and the Y axis
shows pfu/ml.
Fig. 2. A schematic representation of the pOka/vOka chimeric viruses and
sequencing of junction regions. (A) Black rectangles indicate that the
cosmid fragment was pOka in origin. Shaded rectangles indicate that the
cosmid fragment was vOka in origin. J-1, J-2, and J-3 designate the junction
regions between pOka and vOka cosmids for chimeric viruses in which
pOka/vOka cosmids are overlapping. (B) Sequence differences that were
detected between the chimeric viruses, based on comparison with the vOka
sequence, are illustrated in regions where the recombinant viruses have an
overlapping junction between a pOka and a vOka cosmid (Junctions 1, 2,
and 3). Sequence differences that were detected in the vOka cosmid
identified by Sato et al. (2003) in ORF62/71 based on comparison with the
pOka cosmid (ORF62/71).
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implant at day 28. Chimeras H and M grew less well than
Chimera K with day 28 mean titers of 1.7  104 and 1.5 
104 pfu/implant, respectively. Chimera B resembled vOka,
with a mean titer in skin of 1.1  104 pfu/implant at day 28
(Fig. 4). The mean peak titers of the three pOka-like viruses
(pOka, Chimera D, and Chimera G) is significantly greater
than the mean peak titers of the vOka-like viruses (vOka,
Chimera H, Chimera M and Chimera B), with a p value of
0.018 (Student’s t test).
These growth characteristics of chimeric pOka/vOka
viruses in skin were analyzed in relation to the componentsof the recombinant viruses that were derived from the pOka
and vOka cosmids (Table 1). All of the three chimeras, D, G
and K, that incorporated the pOka cosmids, Af117 and
Avr102, had infectious virus yields of z 2.3  104 pfu/
implant. Afl17 and Avr102 included ORFs 30–55 of the
VZV genome (Fig. 1). These segments were derived from
vOka in the chimeras H, M, and B. In contrast to D, G and
K, these chimeras had mean peak titers in skin that were V
1.7  104 pfu/implant. Chimera D, which had a mean peak
titer of 3.0  104 pfu/implant, contained only these two
fragments from pOka, whereas chimeras G and K contained
pOka Afl17 and Avr102 in addition to one other pOka
fragment. This additional fragment was either Fsp73
(Chimera G) or Spe23 (Chimera K). Thus, ORFs 30–55
from pOka were sufficient to yield a pOka-like infection in
skin. The more restricted growth phenotypes of chimeras H,
M, and B in skin xenografts suggested that other regions did
not compensate for the absence of pOka sequence in the
ORF30–55 region.
Experiments with chimeras D, G, and K indicated that
pOka-like infectivity was achieved without pOka Spe14
genes, which include ORFs 21–30. The results with chimera
B indicate that the presence of the pOka genes contained in
Fsp73 alone were not sufficient to overcome its vOka-like
phenotype; these genes include ORFs 1–16.
The two chimeras, D and G, that were as infectious as
pOka in skin, were constructed with the Spe21 cosmid from
vOka. Since the Spe21 cosmid carried ORF62/71 and
ORF63/70, as well as the unique short region of the VZV
genome, which includes genes for gE and gI, the results
suggested that these regions were not dominant over other
regions of the VZV genome in creating the attenuation
phenotype of vOka in skin. Conversely, growth of chimeras
Fig. 4. Growth of pOka/vOka chimeric viruses in skin xenografts in SCIDhu mice. Skin xenografts were inoculated with pOka, the chimeric viruses, or vOka.
Each bar represents the mean titer of infectious virus recovered from skin implants harvested at 7, 14, 21, or 28 days after inoculation; error bars indicate the
standard error (SE). Inoculum titers (PFU/ml) are given for each virus tested.
L. Zerboni et al. / Virology 332 (2005) 337–346 341H and M was reduced even though the Spe23 genome
segment was from pOka.
Skin histology
Infection of skin xenografts with varicella vaccine was
characterized by a relative restriction of replication to the
epidermis, with limited penetration of the dermal layers,
compared to much more extensive cytopathic changes
associated with pOka infection (Moffat et al., 1998a,
1998b). In the current experiments, recombinant pOka and
each of these chimeric viruses tested demonstrated extensive
replication in epidermal tissues with limited penetration into
dermal layers at 21 days after infection. By day 28, the
lesions had expanded significantly with disruption of the
basement membrane at the epidermal/dermal junction and
replication in dermal cell layers and hair follicles. In
comparison, replication of recombinant vOka at day 28
resembled pOka lesions at day 21 with extensive epidermal
replication but limited progression into the dermis (Fig. 5).
Our results indicate that, like the parent Oka strain,
recombinant pOka retains the ability to spread deep intoTable 1
Relationships between patterns of growth in skin, the pOka composition of the
infected melanoma cells
Peak titer in skin
(cfu/implant)
pOka Fsp73 pOka Spe14 pOka
pOka 2.8  104 + + +
D 3.0  104   +
G 2.9  104 +  +
K 2.3  104   +
H 1.7  104 +  
M 1.5  104 + + 
B 1.1  104 +  
vOka 0.9  104   
N: nuclear localization, C: cytoplasmic localization.dermal tissues, whereas recombinant vOka, like varicella
vaccine, exhibits a delayed penetration phenotype.
Intracellular localization of IE62 protein in vitro
The inoculation of melanoma cells with recombinant
pOka and vOka showed a marked difference in the
intracellular localization of IE62 protein, which was
characterized by a prolonged nuclear retention of IE62
protein in vOka-infected cells. In our experiments, IE62
protein was predominantly cytoplasmic by 20 h in cells
infected with recombinant pOka, while IE62 protein
remained predominantly nuclear at 30 h in vOka-infected
cells (Fig. 6) and had only a limited expression in cytoplasm
at 48–72 h. Chimera B, which was constructed from vOka
cosmids, with the exception of the pOka Fsp73 fragment,
had the same IE62 localization phenotype as vOka. Chimera
B was also the most attenuated of the chimeric viruses for
infectivity in skin xenografts. Chimera G, which contained
the vOka ORF62, was also predominantly nuclear. How-
ever, the IE62 nuclear localization phenotype could not be
attributed solely to the presence of ORF62 from the vOkachimeric viruses, and localization of immediate early 62 (IE62) protein in
Afl17 pOka Avr102 pOka Spe23 IE62 localization in
melanoma cells (30 h)
+ + C
+  C
+  N
+ + C
 + C
 + C
  N
  N
Fig. 5. Hematoxylin and eosin staining of skin xenografts. Hematoxylin and eosin staining of uninfected (A), recombinant vOka inoculated (B) or recombinant
pOka inoculated (C) skin xenografts at 28 days post infection. Intact basement membrane representing the epidermal/dermal junction is indicated by a black
arrowhead. Disruption of basement membrane and spread of VZV lesion into dermal layers is indicated by a white arrowhead.
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sion of IE62. Chimeras K, H, and M, all of which contain
pOka ORF62, have cytoplasmic expression of IE62 protein
as well. All of these observations were consistent for each
chimeric virus tested in three separate assays.Discussion
The live attenuated varicella vaccine is the first vaccine
to be licensed in the United States for prevention of a human
herpesvirus infection. Safety, as demonstrated by the
significant reduction in the capacity of vOka to causeFig. 6. Localization of IE62 in melanoma cells infected with pOka/vOka chimeric
fixed and stained with anti-IE62 mAb and counterstained with Texas Red conjug
vOka, (C) chimera H, and (D) chimera B. Magnification 20.varicella, was documented in early clinical trials in Japan
(Takahashi et al., 1974). The clinical evidence for vOka
attenuation is that vaccine-associated rashes occur in only
about 5% of healthy children and adults and that vOka
replication does not occur or is relatively restricted in
vaccinees who have leukemia or other immunosuppressive
conditions that predispose to life-threatening wild-type VZV
infection (Gershon, 2001; White, 1996). Infection of skin
xenografts in SCIDhu mice with vOka was associated with
lower yields of infectious virus, decreased viral protein
synthesis and slower progression of cutaneous lesions
compared to pOka and to VZV-S, another low passage
clinical isolate. Therefore, we have proposed that theviruses. Melanoma cells were infected, incubated for 30 h. Monolayers were
ated-anti-mouse IgG. The panels show IE62 localization for (A) pOka, (B)
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capacity to replicate in skin, which allows a longer interval
for the adaptive immune response to develop after viral
inoculation. According to this hypothesis, infectious vOka
may be cleared before skin lesions are formed and before
cell-associated viremia, with spread to other skin sites of
replication, can occur (Arvin, 2001a, 2001b).
These experiments with chimeric pOka/vOka recombi-
nant viruses suggest that vOka attenuation in human skin is
multi-factorial. Diminished replication in skin was observed
with chimeras M, B, and to a lesser degree with chimera H,
even though different components of the genomes of these
chimeric viruses were derived from vOka cosmids. Con-
versely, chimera D was as infectious as pOka despite
containing only two pOka segments in the recombinant
genome. These observations are consistent with consensus
sequencing which suggests the presence of multiple
nucleotide differences between pOka and vOka that are
predicted to change amino acid residues (Argaw et al., 2000;
Faga et al., 2001; Gomi et al., 2000). Our comparative
analysis of the vOka and pOka consensus sequence data
indicated that 32 viral proteins in vOka have predicted
amino acid substitutions (cmgm.stanford.edu/~jjones/)
(Table 2). Changes have been identified that could affect
all three putative kinetic classes of VZV proteins, including
immediate early regulatory proteins, early proteins and the
late glycoproteins. Genetic heterogeneity has also been
demonstrated when selected VZV ORFs were sequenced
using viral DNA recovered from single plaques in tissue
culture monolayers that were infected with vOka vaccine
preparations (Gomi et al., 2000). Importantly, vOka viruses
recovered from different individuals who had vaccine-
related skin lesions have also demonstrated sequence
heterogeneity when several ORFs were analyzed (QuinlivanTable 2
Analysis of consensus sequence data for V-Oka and P-Oka
ORF Protein aa ORF Protein
24 (UL34)
6 DNA rep 2 28 DNA pol
8 dUTPase 1 29 ssDNA bp
9 (UL49/VP22) 1 31 gB
10 transactivator 3 33 protease
11 (aTIF aux) insert/deleteb 35 (UL24)
14 gC insert/deleteb 36 thy kinase
16 DNA bp 1 37 gH
17 (UL41/vhs) 3c 38 (UL21)
18 ribo reductase 1 39 (UL20)
21 (UL37) 1 44 (UL16)
22 (UL36) 11d 48 alk exonu
Parentheses indicate HSV homologue if VZV protein has not been characterized.
altered vOka sequence.
Sequence comparisons are based on the Merck consensus sequence for vaccine O
Adapted from Cohen and Straus, 2001.
a Frame shift changes C-terminus.
b Insertions/deletions in R-repeats.
c With a 3-nt deletion.
d Two R-repeat insertion/deletion regions with 11 aa differences.et al., 2004). These observations suggest that vOka vaccines
constitute mixtures of VZV genomes with varying genetic
alterations that have accumulated during serial passage in
cultured cells. As a result, the VZV genes and non-coding
regions present in each of the five vOka cosmids, which
were made from cells infected with the varicella vaccine, are
expected to have changes that represent a subset of this
mixed population of vOka genomes. The recombinant vOka
virus was attenuated in skin. Thus, one combination of
changes in the VZV genome that were induced by passage
in human and non-human fibroblasts appears to be sufficient
to confer the attenuation that is observed with the mixed
population in varicella vaccine preparations. The fact that
recombinant pOka remained virulent in skin xenografts
suggests that the steps required to make VZV cosmids from
pOka-infected cells did not introduce attenuating mutations
into the pOka genome.
Nucleotide changes appear to be relatively common in
ORF62/71 in vOka subpopulations. Sequencing of ORF62
in plasmid clones made from cells infected with the varicella
vaccine Oka virus revealed considerable heterogeneity
(Gomi et al., 2000). The A2872G substitution found in
ORF62 in our vOka cosmid was identified in some ORF62
plasmids derived from vaccine Oka virus stocks, but the
T3172C mutation had not been reported previously (Sato et
al., 2003). Nevertheless, our experiments suggest that
ORF62 changes were not sufficient or required to diminish
vOka virulence in skin. Chimera M had this attenuation
phenotype even though ORF62 was derived from pOka.
IE62 protein has been observed within distinct small, dense
nuclear bodies in cultured cells infected with vOka and
occurred with our recombinant vOka virus (Kinchington et
al., 2000). Our experiments suggest that this IE62 local-
ization phenotype in vitro is not related to vOka attenuation.aa ORF Protein aa
1 51 ori bp frame shifta
3 52 helic/primase 3
3 54 (UL6) 2
1 56 (UL4) 1
3
1 58 (UL3) 3
1 60 gL 2
1 62/71 IE62 3
1 64/69 (US10) 1
frame shifta 68 gE 1
1
cl 2
aa = number of amino acid residues in the protein that are changed by the
ka and the Yaminishi consensus sequence for parent Oka.
L. Zerboni et al. / Virology 332 (2005) 337–346344Chimera G had nuclear retention of IE62 but was as
infectious as pOka in skin xenografts.
Quinlivan et al. (2004) demonstrated that rashes
following vOka vaccination were derived from single
clones of the vaccine virus mixture. Our experiments with
chimeric pOka/vOka viruses suggest that VZV genomes
with varying combinations of pOka-derived and vOka-
derived DNA exhibit the attenuation phenotype in skin
whereas other chimeras replicate as well as pOka. These
observations are consistent with the evidence that the
vaccine-related rashes are due to single viral clones and
suggest that the limited number of cutaneous lesions that
occur in some vaccine recipients represent an in vivo
selection of the vOka genomes that retain infectivity for
skin. The importance of the overall attenuation of the vOka
mixture in skin is suggested by our evidence that VZV
passage in fibroblasts attenuated VZV virulence in skin but
not T cells (Moffat et al., 1998a, 1998b). VZV-Ellen,
which has been passaged more than 100 times in cultured
cells was even more impaired for replication in skin
xenografts than vOka. However, vOka and pOka did not
differ in their infectivity for human T cells in thymus/liver
xenografts in vivo. Combining our findings with those of
Quinlivan et al. may provide some further insights about
the etiology of varicella vaccine related rashes. That is,
vOka clones that can replicate more efficiently in skin
would be expected to have retained the capacity to infect T
cells that traffic through the vaccination site; if these T
cells become infected, the selected virus can be transported
to new skin sites of replication, creating additional
cutaneous lesions that would represent the same vOka
clone.
Our studies using recombinants made from cosmids in
the SCIDhu model of VZV pathogenesis demonstrate that
VZV infectivity in skin can be diminished even by a single
amino acid substitution, such as disrupting ORF47 kinase
function in the mutant, rOka47DN, or altering C-terminal
residues in gE (Besser et al., 2003, Moffat et al., 2004).
Changes in non-coding regions can also decrease skin
tropism, as shown with gI promoter mutants (Moffat et al.,
2002; Ito et al., 2003). These findings indicate that VZV
attenuation in skin can be achieved by very restricted
alterations in the genome sequence. The traditional
approach to making a live attenuated viral vaccine by
tissue culture passage has resulted in the production of a
varicella vaccine containing mixtures of viral genomes. As
shown with our chimeric pOka/vOka viruses, the presence
of some vOka genome segments may not confer attenu-
ation, whereas others do. These observations suggest that a
bnext generationQ varicella vaccine could be made as a
recombinant derived as a pOka/vOka chimera and repre-
senting a single VZV genome. As long as the vaccine
contains a predominance of VZV genomes with mutations
that reduce skin virulence, the result is the clinical
experience of vaccine safety that has been observed with
Oka-derived varicella vaccines.Materials and methods
VZV Cosmids
The method for generating vOka recombinant viruses
from four overlapping fragments of genomic DNA in
SuperCos1 cosmid vectors (Stratagene) has been described
(Kemble et al., 2000; Mallory et al., 1997) (Fig. 1A);
subsequently, we made a set of four pOka cosmids with the
same restriction sites as used for vOka cosmids, as well as
five cosmid systems from vOka and pOka (Besser et al.,
2003; Niizuma et al., 2003; Sato et al., 2003). To generate
the five cosmid system, the largest of the four cosmids
(Pme19) was first digested with AflII and AscI (Fig. 1B). A
26.0-kb AscI/AflII fragment, representing the left half of the
Pme19 cosmid was isolated. An AflII/AscI linker was
annealed to the isolated DNA and this fragment was ligated
to the 6.8-kb AscI-digested SuperCos vector to generate the
cosmid pAfl30. After digestion with AscI and AvrII, a 24-kb
fragment representing the right half of the Pme19 cosmid
was isolated, as well as the 4.6-kb AvrII/AscI fragment of
the SuperCos vector. Following isolation, the two DNA
fragments were ligated together to generate the cosmid
pAvr13. The two cosmids, pAfl30 and pAvr13, generated
from Pme19 contain a 7.5-kb overlapping region. An
identical protocol was used to generate two new cosmids,
pAfl17 and pAvr102, from the largest pOka cosmid (Pme2).
Generation of recombinant viruses
Cosmids were electroporated into Top 10F’ E. Coli cells
(Invitrogen) and DNAwas purified using a Qiagen Maxiprep
kit. The method for transfection of VZV cosmid DNA has
been previously described (Mallory et al., 1998). In brief,
cosmid DNAwas digested with Asc1, with the exception of
Avr102 and Avr13 which were digested with Asc1 and AvrII
to release the viral DNA. In order to generate recombinant
pOka virus, the pOka cosmids were mixed to a final
concentration of 100 ng/Al of Fsp73, Spe14, Afl17 and
Avr102, 50 ng/Al of Spe23 and 252 mM CaCl2 in a total of
250 Al. Human melanoma cells were cotransfected with the
intact pOka cosmids (Niizuma et al., 2003). The cells were
grown at 37 8C for up to 28 days, passing at a 1:3 ratio every
3 to 4 days, by which time viral plaques were evident. The
same protocol was used to generate recombinant vOka virus
using the vOka cosmids Fsp4, Spe5, Afl30, Avr13, and
Spe21. In order to produce chimeric viruses, cosmids from
pOka and vOka were mixed prior to transfection. Chimeric
viruses were analyzed by PCR and sequencing of the
junctions between pOka and vOka cosmids.
Replication and IE62 localization in cultured cells in vitro
VZV recombinants were assessed for growth kinetics by
infectious center assay (Mallory et al., 1998; Moffat et al.,
1995). Briefly, VZV-infected melanoma cells were seeded
L. Zerboni et al. / Virology 332 (2005) 337–346 345onto fresh monolayers of melanoma cells in a 6-well plate.
At days 1 through 6 after infection, the infected cell
monolayer was trypsinized, serially diluted, and added to
uninfected Vero cell monolayers in a 24-well plate. After 5
or 6 days, wells were stained with crystal violet, plaques
were counted and the number of infectious center-forming
units (pfu) per ml of inoculum was calculated.
To examine localization of the IE62 protein, melanoma
cells were seeded in 1 ml chamber slides, allowed to grow to
near confluency, and inoculated with the test viruses. After
20, 30, and 48 h, cells were fixed in 2% paraformaldehyde
with 0.1% Triton in phosphate-buffered saline (PBS) for 1 h,
washed five times with PBS for 5 min each, blocked with
5% donkey serum in PBS for 30 min, and incubated
overnight with mouse anti-IE62 antibody (1:750) with 1%
donkey serum in PBS. Chamber slides were washed again
five times in PBS and incubated with a secondary anti-
mouse Texas red conjugated antibody (Jackson Immuno-
Research) for 1 h. After washing, coverslips were mounted
and slides were viewed and photographed at 200. This
assay was done three times for each test virus.
Infection of skin xenografts in vivo
Construction of human skin xenografts in SCID mice and
subsequent inoculation with VZV or mock-infected cells
was done as described previously (Moffat et al., 1998a,
1998b). Protocols for animal studies were approved by the
Stanford University Administrative Panel on Laboratory
Animal Care; human fetal tissues were obtained with
informed consent according to federal and state regulations.
Briefly, 3–5 weeks after implantation, mice were anesthe-
tized and bilateral skin xenografts were inoculated with
VZV-infected human lung fibroblasts (HELF) cells by
scarification and direct injection using a 27-gauge needle.
Control xenografts were inoculated with an equal number of
uninfected HELF cells. At days 7, 14, 21, and 28 after
inoculation, xenografts were removed and prepared for
infectious center assay and immunohistochemistry (Moffat
et al., 1998a, 1998b). Five implants were evaluated for each
virus per time point. For viral titrations, half of the xenograft
was mechanically homogenized in 1 ml of phosphate-
buffered saline (PBS, pH 7.4). An equal volume of the
homogeneous lysate (100 Al) was serially diluted for plaque
assay. Plaque assays were performed in triplicate for each
implant. For immunohistochemistry, the remainder of the
xenograft was formalin-fixed and paraffin-embedded. VZV
proteins were detected with a high-titer polyclonal human
anti-VZV IgG; human IgG from a VZV non-immune donor
was used as a negative control.Acknowledgments
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